This hierarchy explains potency and receptor activity differences. If you prefer a powder format, browse MGM-15 powders.
- Mitragynine acts as the parent alkaloid → baseline activity
- 7-hydroxymitragynine acts as an oxidized metabolite → increased potency
- MGM-15 acts as a hydrogenated derivative → enhanced receptor affinity
- MGM-16 (pseudoindoxyl form) acts as a rearranged derivative → altered signaling
The next section defines mitragynine as the root compound. If you prefer a tablet format, browse MGM-15 tablets.
What is the kratom alkaloid family tree?
The kratom alkaloid family tree maps structural and metabolic relationships between mitragynine and its derivatives. Mitragynine transforms into 7-hydroxymitragynine, which further converts into advanced derivatives like MGM-15 and MGM-16. For another safety read, see Is MGM-15 Stronger than 7oh?.
TL;DR
- Mitragynine acts as the base alkaloid in kratom
- 7-OH increases potency through oxidation
- MGM-15 enhances receptor affinity via hydrogenation
- MGM-16 alters signaling through pseudoindoxyl structure
What is mitragynine and why is it the parent alkaloid?
Mitragynine is the primary alkaloid in Mitragyna speciosa and serves as the biochemical precursor to most kratom derivatives. It defines the structural backbone for downstream modifications.
Mitragynine shows partial μ-opioid receptor agonism with moderate potency.
| Attribute | Value |
|---|---|
| Source | Kratom leaves |
| Class | Indole alkaloid |
| Receptor activity | Partial μ-agonist |
| Relative potency | Low |
Key properties:
- Mitragynine forms the base structure → indole scaffold
- Mitragynine undergoes metabolism → produces active derivatives
- Mitragynine shows lower receptor affinity → milder effects
The next section explains 7-hydroxymitragynine formation.
What is 7-hydroxymitragynine and how does it form?
7-hydroxymitragynine is an oxidized metabolite of mitragynine formed through enzymatic processes in the liver. It shows significantly higher μ-opioid receptor affinity.
- Mitragynine undergoes oxidation → forms 7-OH
- 7-OH increases receptor binding → stronger analgesia
- 7-OH acts as a key active metabolite → drives pharmacological effects
Potency comparison:
| Compound | Relative Potency |
|---|---|
| Mitragynine | Low |
| 7-hydroxymitragynine | High |
This metabolite acts as a bridge between natural and semi-synthetic derivatives. The next section explains MGM-15.
What is MGM-15 in the alkaloid pathway?
MGM-15 (dihydro-7-hydroxymitragynine) is a hydrogenated derivative of 7-hydroxymitragynine. Hydrogenation reduces double bonds and increases receptor binding stability.
- 7-OH undergoes hydrogenation → forms MGM-15
- MGM-15 increases μ-receptor affinity → stronger effects
- MGM-15 shows enhanced structural stability → prolonged activity
Structural role:
| Stage | Transformation |
|---|---|
| Mitragynine | Base compound |
| 7-OH | Oxidized metabolite |
| MGM-15 | Hydrogenated derivative |
MGM-15 represents a potency-enhanced intermediate. The next section introduces MGM-16.
What is MGM-16 (pseudoindoxyl kratom)?
MGM-16 refers to pseudoindoxyl derivatives formed through structural rearrangement of mitragynine or 7-OH compounds. These derivatives show distinct receptor signaling behavior.
Pseudoindoxyl formation alters the indole structure into a different configuration.
- MGM-16 forms via rearrangement → pseudoindoxyl structure
- MGM-16 changes receptor signaling → biased agonism
- MGM-16 may reduce certain side effects → altered pathway activation
Key distinction:
| Feature | MGM-15 | MGM-16 |
|---|---|---|
| Structure | Hydrogenated | Rearranged (pseudoindoxyl) |
| Mechanism | Strong agonist | Biased agonist (hypothesized) |
| Stability | High | Variable |
MGM-16 represents a structurally advanced derivative. The next section compares MGM-15 vs MGM-16 directly.
What is the difference between MGM-15 and MGM-16?
MGM-15 and MGM-16 differ in chemical structure and receptor signaling. MGM-15 is hydrogenated, while MGM-16 is a pseudoindoxyl rearrangement product.
Core differences:
- MGM-15 increases receptor affinity → stronger direct activation
- MGM-16 alters signaling pathways → potential bias toward G-protein signaling
- MGM-15 maintains indole structure → stable configuration
- MGM-16 modifies core structure → different pharmacodynamics
Comparison table:
| Attribute | MGM-15 | MGM-16 |
|---|---|---|
| Chemical type | Hydrogenated derivative | Pseudoindoxyl derivative |
| Receptor binding | Very high | High but different signaling |
| Research depth | Limited | Very limited |
| Functional role | Potency enhancement | Signaling modification |
These differences drive distinct pharmacological profiles. The next section explains derivative classification.
What are kratom alkaloid derivatives?
Kratom alkaloid derivatives are chemically modified or metabolically transformed compounds based on mitragynine’s structure. These derivatives alter potency, duration, and receptor interaction.
Types of derivatives:
- Oxidized derivatives → 7-hydroxymitragynine
- Hydrogenated derivatives → MGM-15
- Rearranged derivatives → pseudoindoxyl (MGM-16)
- Synthetic analogs → lab-designed modifications
Derivative classification depends on structural transformation type. The next section explains why these transformations matter.
Why do mitragynine derivatives matter in pharmacology?
Mitragynine derivatives matter because structural changes directly affect receptor binding, signaling pathways, and pharmacological outcomes.
- Structural modification changes affinity → alters potency
- Chemical rearrangement changes signaling → affects side effects
- Hydrogenation increases stability → prolongs duration
Research significance:
- Supports opioid alternative development
- Enables biased agonism studies
- Improves structure–activity relationship (SAR) models
These derivatives help researchers understand receptor selectivity. The next section explains research gaps.
What research gaps exist in kratom derivatives?
Kratom derivatives lack comprehensive human studies. Most data comes from preclinical research and structural analysis.
- MGM-15 lacks clinical trials → limited human data
- MGM-16 lacks pharmacokinetic studies → unknown metabolism
- Pseudoindoxyl derivatives lack safety profiles → unclear risk
Key limitations:
- No standardized dosing
- Limited toxicology data
- Incomplete long-term studies
These gaps restrict medical application. The next section summarizes key facts.
What are the key facts about the kratom alkaloid family tree?
The kratom alkaloid family tree shows a progression from natural compounds to advanced derivatives with increasing potency and complexity.
- Mitragynine acts as the base compound
- 7-OH increases potency through oxidation
- MGM-15 enhances affinity via hydrogenation
- MGM-16 alters signaling through rearrangement
This progression explains pharmacological diversity. The next section provides FAQs and quick summaries.
FAQ
What are mitragynine derivatives?
Mitragynine derivatives are compounds formed by modifying or metabolizing mitragynine. These include 7-hydroxymitragynine, MGM-15, and pseudoindoxyl derivatives like MGM-16.
What is the strongest kratom derivative?
7-hydroxymitragynine and its derivatives, including MGM-15, show the highest μ-opioid receptor affinity among known kratom-related compounds.
What is pseudoindoxyl kratom?
Pseudoindoxyl kratom refers to structurally rearranged derivatives of mitragynine. These compounds, such as MGM-16, exhibit altered receptor signaling and potential biased agonism.
How is MGM-15 different from mitragynine?
MGM-15 is a hydrogenated derivative of 7-OH, while mitragynine is the natural parent compound. MGM-15 shows significantly higher receptor affinity and potency.
What is the difference between 7-OH and MGM-15?
7-OH is an oxidized metabolite, while MGM-15 is a hydrogenated derivative. MGM-15 shows increased structural stability and potentially stronger receptor binding.
Is MGM-16 more advanced than MGM-15?
MGM-16 represents a structurally more complex derivative due to pseudoindoxyl rearrangement. It may exhibit different receptor signaling, but research remains very limited.